Mizuho Reiterates Buy Rating on Sol-Gel Technologies Ltd. with $285 Target
Mizuho reaffirmed its buy rating for Sol-Gel Technologies Ltd. with a $285 price target, a 292.18% upside from the current price.
Key Points
- Mizuho reiterated its buy rating for Sol-Gel Technologies Ltd. (SLGL) on June 24, 2026, with a $285 price target.
- Mizuho's $285 price target implies 292.18% upside from Sol-Gel Technologies Ltd.'s ($SLGL) current $72.67 share price.
- Shares of SLGL were trading at $73.4 on Friday, with a market cap of approximately $237.6 million.
- Opaleye Management Inc. and Citadel Advisors LLC adjusted their positions in Sol-Gel, with Citadel increasing by 49.9%.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Mizuho has reiterated its buy rating for Sol-Gel Technologies Ltd. (NasdaqCM: SLGL) with a price target of $285. This announcement was made on June 24, 2026, by analyst Uy Ear. Shares of Sol-Gel traded at $73.4 on Friday.
Mizuho vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Sol-Gel Technologies Ltd.
Various institutions have been adjusting their holdings in Sol-Gel Technologies. Opaleye Management Inc. increased its stake by 46,261 shares, ending with 500,000 shares valued at approximately $39.6 million, representing a 10.2% increase. Great Point Partners LLC opened a new position with 274,363 shares worth about $21.7 million. Phoenix Financial Ltd. trimmed its stake by 7,366 shares, leaving it with 210,849 shares valued at around $16.7 million, a decrease of 3.4%. Citadel Advisors LLC significantly boosted its holdings, adding 30,946 shares for a total of 37,145 shares valued at $2.9 million, marking a 499.2% increase.
Sol-Gel Technologies Ltd. Stock Up 5.6%
On Friday, shares of Sol-Gel Technologies Ltd. (NasdaqCM: SLGL) traded near $73.4. The company has a market capitalization of roughly $237.6 million. Sol-Gel's forward P/E ratio isn't meaningful as the company is not currently profitable. The stock has seen a 52-week low of $6.96 and a high of $97.97, with a 50-day moving average of $72.96 and a 200-day moving average of $58.16. Sol-Gel has a beta of 1.127, indicating its stock is slightly more volatile than the market. The company maintains a strong liquidity position with a current ratio of 8.837 and a quick ratio of 8.537.
$SLGL price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Sol-Gel Technologies reported revenue of $18.5 million, though it experienced a revenue decline of 89.5%. The company posted a negative net margin of 5.7% and a return on equity of -2.9%. The next earnings release is expected on May 28, 2026.
Insider Buying and Selling at Sol-Gel Technologies Ltd.
Insider transactions at Sol-Gel Technologies include several buys by Opaleye Management Inc., such as 1,563 shares at $64.43 on May 20, 2026, and 1,937 shares at $66.87 on May 13, 2026. Additionally, Yosef Itzik sold 1,556 shares at $87.63 on February 25, 2026, under a planned sale.
Analysts Set New Price Targets
On June 24, 2026, Mizuho initiated coverage with a buy rating and a $285 price target. HC Wainwright & Co. also maintained its buy rating earlier this year with a target of $110. The consensus among analysts is a strong buy, with a mean target price of $193 based on three analyst opinions.
About Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd. is a biotechnology company based in Ness Ziona, Israel, focusing on developing topical dermatological drugs. It offers products like Twyneo for acne and Epsolay for rosacea. The company is also working on treatments for Gorlin Syndrome and Olmsted Syndrome. Led by CEO Mr. Moshe Arkin, Sol-Gel collaborates with various pharmaceutical companies and operates internationally.
Bottom Line
Mizuho's reiterated buy rating and $285 price target underscore confidence in Sol-Gel Technologies Ltd.'s potential. Investors often track such analyst ratings for insights into a company's future prospects. It's important to remember that these ratings reflect analysts' views at the time of the report and may not predict future stock performance.
Get Sol-Gel Technologies Ltd. alerts
New 13F filings, insider trades, and analyst moves on $SLGL, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.